Summary
45.86 -0.68(-1.45%)09/05/2024
Iradimed Corp (IRMD)
Iradimed Corp (IRMD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.45 | -2.44 | 3.60 | 6.05 | 7.86 | -3.26 | 161.81 | 387.13 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 45.86 | |
| Open | 46.64 | |
| High | 46.64 | |
| Low | 45.65 | |
| Volume | 44,662 | |
| Change | -0.68 | |
| Change % | -1.45 | |
| Avg Volume (20 Days) | 36,163 | |
| Volume/Avg Volume (20 Days) Ratio | 1.24 | |
| 52 Week Range | 36.12 - 50.93 | |
| Price vs 52 Week High | -9.96% | |
| Price vs 52 Week Low | 26.95% | |
| Range | -1.68 | |
| Gap Up/Down | -0.04 | |
Fundamentals | ||
| Market Capitalization (Mln) | 590 | |
| EBIDTA | 21,585,276 | |
| PE Ratio | 31.1357 | |
| PEG Ratio | 4.4600 | |
| WallStreet Target Price | 62.50 | |
| Book Value | 6.0110 | |
| Earnings Per Share | 1.4000 | |
| EPS Estimate Current Quarter | 0.3300 | |
| EPS Estimate Next Quarter | 0.3700 | |
| EPS Estimate Current Year | 1.5300 | |
| EPS Estimate Next Year | 1.7100 | |
| Diluted EPS (TTM) | 1.4000 | |
| Revenues | ||
| Profit Marging | 0.2648 | |
| Operating Marging (TTM) | 0.2698 | |
| Return on asset (TTM) | 0.1587 | |
| Return on equity (TTM) | 0.2552 | |
| Revenue TTM | 67,685,328 | |
| Revenue per share TTM | 5.3630 | |
| Quarterly Revenue Growth (YOY) | 0.1370 | |
| Quarterly Earnings Growth (YOY) | 0.1850 | |
| Gross Profit (TTM) | 41,282,403 | |
| Dividends | ||
| Dividend Share | 0.1500 | |
| Dividend Yield | 0.0138 | |
| Valuations | ||
| Trailing PE | 31.1357 | |
| Forward PE | 24.0964 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.2985 | |
| Revenue Enterprise Value | 7.2227 | |
| EBITDA Enterprise Value | 22.7656 | |
| Shares | ||
| Shares Outstanding | 12,664,200 | |
| Shares Float | 6,529,147 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 37.04 | |
| Institutions (%) | 55.61 | |
08/03 18:17 EST - seekingalpha.com
IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2024 Results Conference Call August 1, 2024 12:00 PM ET Company Participants Roger Susi - President and Chief Executive Officer Matt Garner - Controller Conference Call Participants Frank Takkinen - Lake Street Capital Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter of 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, August 1, 2024, and contains time-sensitive accurate information only today.
IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2024 Results Conference Call August 1, 2024 12:00 PM ET Company Participants Roger Susi - President and Chief Executive Officer Matt Garner - Controller Conference Call Participants Frank Takkinen - Lake Street Capital Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter of 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, August 1, 2024, and contains time-sensitive accurate information only today.
08/01 10:50 EST - zacks.com
IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.36 per share a year ago.
IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.36 per share a year ago.
08/01 09:29 EST - globenewswire.com
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
07/25 08:30 EST - globenewswire.com
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions.
06/07 08:30 EST - globenewswire.com
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market
WINTER SPRINGS, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market
WINTER SPRINGS, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.
05/04 13:27 EST - seekingalpha.com
IRADIMED CORPORATION (IRMD) Q1 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2024 Results Conference Call May 2, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Frank Takkinen - Lake Street Capital Operator Welcome to IRADIMED CORPORATION First Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode, and at the end of the call, we will conduct a question-and-answer session.
IRADIMED CORPORATION (IRMD) Q1 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2024 Results Conference Call May 2, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Frank Takkinen - Lake Street Capital Operator Welcome to IRADIMED CORPORATION First Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode, and at the end of the call, we will conduct a question-and-answer session.
05/02 08:30 EST - globenewswire.com
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
04/25 16:05 EST - globenewswire.com
IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd
WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd
WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
03/13 16:30 EST - globenewswire.com
IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference
WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA.
IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference
WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA.
02/08 18:20 EST - seekingalpha.com
IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript
IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript
IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript
IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript
02/08 08:05 EST - globenewswire.com
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results
WINTER SPRINGS, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months and year ended December 31, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results
WINTER SPRINGS, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months and year ended December 31, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
02/01 16:05 EST - globenewswire.com
IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.
WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.
WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
01/09 08:30 EST - globenewswire.com
IRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue
WINTER SPRINGS, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (‘MRI”) compatible medical devices, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. The fourth-quarter revenue totaled approximately $17.5 million, bringing revenue for 2023 to approximately $65.6 million, up 23% from the prior year.
IRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue
WINTER SPRINGS, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (‘MRI”) compatible medical devices, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. The fourth-quarter revenue totaled approximately $17.5 million, bringing revenue for 2023 to approximately $65.6 million, up 23% from the prior year.
01/02 16:30 EST - globenewswire.com
IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference
WINTER SPRINGS, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42nd Annual J.P.
IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference
WINTER SPRINGS, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42nd Annual J.P.
12/12 10:00 EST - globenewswire.com
IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share
WINTER SPRINGS, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the quarterly dividend are payable on January 12, 2024, to shareholders of record at the close of business on December 22, 2023.
IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share
WINTER SPRINGS, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the quarterly dividend are payable on January 12, 2024, to shareholders of record at the close of business on December 22, 2023.
11/17 09:46 EST - zacks.com
5 Small Hidden Gems for the Rest of 2023
We have narrowed our search to five small-cap (market capital < $1 billion) stocks. These are: HCI, LMB, IRMD, GHM, MNTX.
5 Small Hidden Gems for the Rest of 2023
We have narrowed our search to five small-cap (market capital < $1 billion) stocks. These are: HCI, LMB, IRMD, GHM, MNTX.
11/03 13:30 EST - seekingalpha.com
IRadimed Corporation (IRMD) Q3 2023 Earnings Call Transcript
IRadimed Corporation (IRMD) Q3 2023 Earnings Call Transcript
IRadimed Corporation (IRMD) Q3 2023 Earnings Call Transcript
IRadimed Corporation (IRMD) Q3 2023 Earnings Call Transcript
11/03 08:00 EST - globenewswire.com
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results
WINTER SPRINGS, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results
WINTER SPRINGS, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
09/22 08:16 EST - zacks.com
4 Top Profitable Stocks to Invest in Using Net Income Ratio
NVIDIA (NVDA), iRadimed (IRMD), Perdoceo Education (PRDO) and Axcelis Technologies (ACLS) have been selected as the top picks with a high net income ratio.
4 Top Profitable Stocks to Invest in Using Net Income Ratio
NVIDIA (NVDA), iRadimed (IRMD), Perdoceo Education (PRDO) and Axcelis Technologies (ACLS) have been selected as the top picks with a high net income ratio.
09/08 08:17 EST - zacks.com
Top 3 Profitable Stocks to Buy Now Using Net Income Ratio
iRadimed (IRMD), PulteGroup (PHM) and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.
Top 3 Profitable Stocks to Buy Now Using Net Income Ratio
iRadimed (IRMD), PulteGroup (PHM) and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.